Banca de DEFESA: Lais Vaz da Costa

Uma banca de DEFESA de DOUTORADO foi cadastrada pelo programa.
STUDENT : Lais Vaz da Costa
DATE: 14/11/2023
TIME: 09:00
LOCAL: Via Microsoft Teams
TITLE:

"Cytotoxicity assays with Lipid Nanoparticles Solids associated with Docetaxel in a cell line Gastric Adenocarcinoma (AGS)".

KEY WORDS:

Stomach cancer, Antitumor effect, Nanotechnology, Metabolism

PAGES: 169
BIG AREA: Ciências Biológicas
AREA: Biologia Geral
SUMMARY:

Gastric cancer is a global health problem, being among the 10 most common types of cancer worldwide. Despite recent advances in cancer therapy, over the years there has been little change in cure and survival rates in patients suffering from gastric cancer. Docetaxel (DTX), one of the most used drugs for the treatment of adenocarcinomas, has a mechanism of action in inhibiting mitosis and cell division, which may cause hypersensitivity, nephrotoxicity, fluid retention and neutropenia. However, its encapsulation in solid lipid nanoparticles (NLS) could reduce these problems, improving its effectiveness and directly transporting the drug to interact with specific tumor cells. NLS-DTX showed greater cytotoxicity against cancer cells (AGS), demonstrating an IC50 value lower than the concentration of free DTX, after 24 h of treatment, evidencing the efficiency of nanoparticles. Through morphological analysis, it was observed that the cells assumed a rounded shape and decreased cytoplasmic projections after treatment. NLS-DTX and DTX induced damage to microtubules, binding proteins and nucleus fragmentation, in addition to impairing cell adhesion, proliferation and migration. It also showed changes in tests involving cell organelles (mitochondria and lysosomes) and cell metabolism. The NLS did not show significant toxicity in the AGS tumor lineage in any of the assays, behaving similarly to the untreated control. Therefore, with the results of this work, it was possible to conclude that the association of DTX with NLS was efficient, presenting cytotoxic action in gastric adenocarcinoma cells, and favoring the use of this formulation in drug administration.

COMMITTEE MEMBERS:
Presidente - 404374 - SONIA NAIR BAO
Externa ao Programa - 1562125 - ANDREA BARRETTO MOTOYAMA - UnBExterna ao Programa - 2932843 - LAISE RODRIGUES DE ANDRADE - UnBExterno à Instituição - ALEXANDRE BRUNI CARDOSO - USP
Externa à Instituição - MARCIA CRISTINA OLIVEIRA DA ROCHA - IB/SP